Please use this identifier to cite or link to this item:
https://doi.org/10.18632/aging.203598
Title: | Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: A case-control study | Authors: | Ng, Ted Kheng Siang Coughlan, Christina Heyn, Patricia C. Tagawa, Alex Carollo, James J. Kua, Ee Heok Mahendran, Rathi |
Keywords: | BDNF cerebral palsy discriminative accuracy hs-CRP mild cognitive impairment |
Issue Date: | 4-Oct-2021 | Publisher: | Impact Journals LLC | Citation: | Ng, Ted Kheng Siang, Coughlan, Christina, Heyn, Patricia C., Tagawa, Alex, Carollo, James J., Kua, Ee Heok, Mahendran, Rathi (2021-10-04). Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: A case-control study. Aging 13 (19) : 22666-22689. ScholarBank@NUS Repository. https://doi.org/10.18632/aging.203598 | Rights: | Attribution 4.0 International | Abstract: | Background: Previous meta-analyses examining the continuum of Alzheimer’s disease (AD) concluded significantly decreased peripheral brain-derived neurotrophic factor (BDNF) in AD. However, across different meta-analyses, there remain inconsistent findings on peripheral BDNF levels in individuals with mild cognitive impairment (MCI). This issue has been attributed to the highly heterogenous clinical and laboratory factors. Thus, BDNF’s level, discriminative accuracy for identifying all-cause MCI and its subtypes, and its associations with other biomarkers and neurocognitive domains, remain largely unknown. Methods: To address this heterogeneity, we compared a healthy control cohort (n=56, 45 female) to an MCI cohort (n=40, 28 female), to determine whether plasma BDNF, hs-CRP, and DHEA-S can differentiate healthy from MCI individuals, including two MCI subtypes (amnestic [aMCI] and non-amnestic [non-aMCI]). The associations between BDNF with other biomarkers and neurocognitive tests were examined. Adults with cerebral palsy were included as sensitivity analyses. Results: Compared to healthy controls, BDNF was significantly higher in all-cause MCI, aMCI, and non-aMCI. Furthermore, BDNF had good (AUC=0.84, 95% CI=0.74 to 0.95, p<0.001) and excellent discriminative accuracies (AUC=0.92, 95% CI=0.84 to 1.00, p<0.001) for all-cause MCI and non-amnestic MCI, respectively. BDNF was significantly and positively associated with plasma hs-CRP (?=0.26, 95% CI=0.02 to 0.50, p=0.038), despite attenuated association upon controlling for BMI (?=0.15, 95% CI=-0.08 to 0.38, p=0.186). Multiple inverse associations between BDNF and detailed neurocognitive tests were also detected. Conclusions: These findings suggest BDNF is increased as a compensatory mechanism in preclinical dementia, supporting the neurotrophic and partially the inflammatory hypotheses of cognitive impairment. © 2021 Ng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited | Source Title: | Aging | URI: | https://scholarbank.nus.edu.sg/handle/10635/233111 | ISSN: | 1945-4589 | DOI: | 10.18632/aging.203598 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_18632_aging_203598.pdf | 770.63 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License